Overview

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Status:
Recruiting

Trial end date:
2023-07-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if vebicorvir (VBR, ABI-H0731) in combination with AB-729 is safe and effective in participants with chronic hepatitis B infection (cHBV) receiving a standard of care nucleos(t)ide/reverse transcriptase inhibitor (SOC NrtI).

Phase:

Phase 2

Details

Lead Sponsor:

Assembly Biosciences

Collaborator:

Arbutus Biopharma Corporation

Treatments:

Entecavir
Tenofovir